And I’ve got a strong feeling you’ll be hearing all about it on CNBC, next month. Mass media exposure is just one reason why you’ll want to consider grabbing shares, right now.

The company priced near the very top of its range. This blockbuster medical IPO isn't just another ticker; it's like discovering a hidden vault of cash in the hospital basement. 

We're talking a colossus that's been feeding the entire U.S. healthcare beast for years—gloves, masks, bandages, catheters, the high-tech wound dressings that heal faster than you can say HIPAA. 

They've got warehouses humming in every state, trucks rolling 24/7, and their own factories cranking out stuff no one else makes as cheap or reliable. 

"Hands down the best value on the Street."

— Stuart Walton, General Partner, Trek Capital Management

SentimentTrader blends 25 years of market analysis with machine-driven technology to deliver institutional-quality research at a fraction of the cost. From the Smart Money/Dumb Money Confidence index to comprehensive backtesting tools, it's everything serious traders need in one platform.

[See what the pros are reading →]

Revenue clocked $27 billion in the last twelve months, up a steady 10%... even as supply snags wrecked smaller players.

Why? 

Vertical integration. They own the raw materials, the plants, the logistics. Competitors like Henry Schein or Owens & Minor? Solid, but this one's got scale that could turn dollars into fortunes. 

Margins hover around 18-20% operating, free cash flow north of $3 billion annually… numbers that scream buy and hold forever.

But wait, the real thrill is the team behind it. 

The underwriters.

Goldman Sachs and Morgan Stanley aren't just names; they're the sharks that make deals swim. Add J.P. Morgan and BofA Securities as joint bookrunners, and you've got a syndicate of forty-plus banks: Barclays, Citi, Deutsche, Jefferies, UBS, Wells Fargo… you could paper Wall Street with their logos. 

Now, this wasn't a sleepy filing; it upsized from $4 billion to over $6 billion in proceeds, with institutions clawing for allocations. 

Retail got crumbs, sure, but that's where the edge is. Analysts are already slapping buy ratings left and right, projecting 12-15% EPS growth through 2027.

The potential? Sky-high. 

Healthcare's a $4 trillion monster, growing 6-8% yearly as boomers need more dialysis, joints replaced, scans galore.

This company? IPO Stream Premium members are getting ticker and trading details on this one. So, check your inbox!

The company is already in 90% of hospitals, but international expansion—Europe, Asia—could add billions.

Customer experience is undergoing a seismic shift, and Gladly is leading the charge with The Gladly Brief.

It’s a monthly breakdown of market insights, brand data, and investor-level analysis on how AI and CX are converging.

Learn why short-term cost plays are eroding lifetime value, and how Gladly’s approach is creating compounding returns for brands and investors alike.

Join the readership of founders, analysts, and operators tracking the next phase of CX innovation.

Subscribe here to stay informed and ahead of the curve.

Subscribe now

Bolt-ons like their past buys of smaller med-tech firms mean they innovate on the fly, ditching low-margin generics for branded gold like antimicrobial coatings or AI-driven supply tools. 

Coming off private equity ownership, the books seem pristine. I see no debt bombs, just growth ammo. ESG folks love it too: sustainable sourcing, reduced plastic waste initiatives that actually work. 

Valuation-wise, at $29, it's trading around twelve times next-year earnings. A bargain compared to S&P health giants at eighteen-plus. Meaning its initial offering may already be at a discount to its peers.

We're recommending it as a serious consideration to premium members because this is rare: stable moat, inflation-proof pricing power, recession-resistant demand. 

Imagine owning a piece of every bandage, blanket and ventilator in hospitals nationwide… with the potential of steady dividends later, maybe special ones too. 

If rates drop, it pops; if not, it's still a cash cow.

Retail forums are lit up, but smart money's quiet… classic sign of conviction. 

Bottom line, the way I see it, this IPO is not a gamble. It's stacking chips in a game that looks rigged to win in the long-term.

Grab it before CNBC breathlessly covers it next month. Our IPO Stream Premium members are getting the trade alert momentarily…

So, if you’re not a member yet, now IS THE TIME.

Trust me, you don't want to miss the boat on this powerhouse.

To upgrade to premium, simply click HERE.

Tim